Kala Pharmaceuticals

Kala Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based Mucus Penetrating Particles, or MPP, technology, with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

KALA BIO, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.

Shares of Kala Pharmaceuticals (NASDAQ:KALA) fell 0.5% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 9.26% over the past year to ($0.49), which beat the estimate of ($0.68).

Kala Pharmaceuticals: Q1 Earnings Insights

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported financial results for the first quarter ended March 31, 2021 and provided a corporate update. “We are early in the launch of EYSUVIS and encouraged by our progress to establish the product as the first and only prescription therapy specifically for the short-term treatm

Kala Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report first quarter 2021 financial results on Wednesday, May 5, 2021. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:00 a.m. ET. The dial-in numbers to access the conference call a

Kala Pharmaceuticals to Report First Quarter 2021 Financial Results and Host Conference Call

Kala Pharmaceuticals' Eysuvis, a corticosteroid-based drug, was approved for both signs and symptoms of dry eye disease last year and sale calls began on Jan 4th 2021. The market uptake of Eysuvis has been good so far and will likely speed up further after more insurers come on board.

Kala Pharmaceuticals Has Good Short- And Long-Term Prospects

Kala Pharmaceuticals has had a torrid time growing sales of its first approved ocular therapy Inveltys, for postoperative pain, which earned just $6.1m in FY20. In October last year, Kala won approval for Eysuvis, a corticosteroid treatment for short-term symptoms of dry eye disease - sales could be anything from $350m to >$1bn.

Kala Pharmaceuticals: Eye Treatment Specialist With Much To Prove May Have Just The Product

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that Cigna has added EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% as a preferred brand on its commercial formulary, effective May 15, 2021. “We are pleased to announce the addition of EYSUVIS to Cigna's preferred formulary, reflecting a significant expan

Kala Pharmaceuticals Announces Preferred Position for EYSUVIS™ on Cigna

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that management will participate in the following virtual healthcare investor conferences in March. H.C. Wainwright Global Life Sciences Conference Date: March 9-10, 2021 Pre-recorded presentation will be made available beginning Tuesday, March 9, 2021 at 7:00 am ET Op

Kala Pharmaceuticals to Present at Upcoming Investor Conferences in March

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q4 2020 Results - Earnings Call Transcript

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided a corporate update. “2020 was a pivotal year for Kala, highlighted by U.S. Food and Drug Administration (FDA) approval of EYSUVIS, the first and only prescription therapy specifi

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report fourth quarter and full year 2020 financial results on Thursday, February 25, 2021. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:00 a.m. ET. The dial-in numbers to access t

Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that Express Scripts, one of the leading pharmacy benefit managers (PBM) in the United States, has added EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% to its National Preferred, Basic and High Performance Formularies, effective February 5, 2021. EYSUVIS

Kala Pharmaceuticals Announces EYSUVIS™ Now Covered by Express Scripts

Kala Pharma (KALA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kala Pharmaceuticals (KALA) Expected to Beat Earnings Estimates: Should You Buy?

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced the launch of EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. EYSUVIS is now available in national and regional U.S. pharmaceutical distribution centers. Patients

Kala Pharmaceuticals Announces Availability of EYSUVISTM for the Treatment of Dry Eye Disease and Provides Update on Development Pipeline

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will participate in two investor conferences in January. Mark Iwicki, Chairman and Chief Executive Officer of Kala Pharmaceuticals, is scheduled to present at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 9:10 a.m. ET. Addi

Kala Pharmaceuticals to Present at Upcoming Investor Conferences in January

Kala Pharmaceuticals Should Have Limited Downside With Eysuvis Now Approved

The Play On Kala Pharmaceuticals

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today provided an update on its plans to launch EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. “We continue to make significant progress on our plans to launch EYSUVIS and establ

Kala Pharmaceuticals Provides Update on Launch Plans for EYSUVISTM for the Treatment of Dry Eye Disease

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present at the Jefferies 2020 Virtual London Healthcare Conference. Mark Iwicki, Chairman and Chief Executive Officer of Kala Pharmaceuticals, is scheduled to participate in a fireside chat on Tuesday, November 17, 2020 at 2:05 p.m. GMT (9:05 a.m. ET). To

Kala Pharmaceuticals to Present at the Jefferies 2020 Virtual London Healthcare Conference

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q3 2020 Results - Earnings Call Transcript

Kala Pharma (KALA) delivered earnings and revenue surprises of -13.64% and 9.74%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Kala Pharmaceuticals (KALA) Reports Q3 Loss, Tops Revenue Estimates

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported financial results for the third quarter ended September 30, 2020 and provided a corporate update. “We are pleased with our third quarter results and the fourth quarter of 2020 is off to a strong start following the recent FDA approval of EYSUVIS, which we plan to launch

Kala Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report third quarter 2020 financial results on Thursday, November 5, 2020. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:00 a.m. ET. The dial-in numbers to access the conference ca

Kala Pharmaceuticals to Report Third Quarter 2020 Financial Results and Host Conference Call

Good news from the FDA translated to bad news for Kala's share price.

Why Kala Pharmaceuticals Stock Sank Today

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that the U.S. Food and Drug Administration (FDA) has approved EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. “The FDA approval of EYSUVIS as the first prescription

Kala Pharmaceuticals Announces FDA Approval of EYSUVIS™ for the Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease

Investors need to pay close attention to Kala Pharmaceuticals (KALA) stock based on the movements in the options market lately.

News for Kala Pharmaceuticals Stock (KALA)